Life Science Start-Ups: Venture Funding, July-August 2014
• By Deanna Kamienski, Beth Allan, Amanda Micklus, and Maureen Riordan
Derived from Strategic Transactions, a fully searchable premium source for tracking life sciences deal activity, the Venture Funding column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced May through June 2014.
Senseonics closes $20mm late-stage round
Senseonics Holdings Inc. (formerly Sensors for Medicine & Science; developing a continuous glucose monitoring system) raised $20mm in what looks to be its Series E round to returning shareholders...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.
Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.
The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.
Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.
